American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer

被引:534
作者
Nag, S
Beyer, D
Friedland, J
Grimm, P
Nath, R
机构
[1] Amer Brachytherapy Society, Clin Res Comm, Prostate Brachytherapy Qual Assurance Grp, Reston, VA USA
[2] Ohio State Univ, Columbus, OH 43210 USA
[3] Arizona Oncol Serv, Phoenix, AZ USA
[4] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
[5] Swedish Med Ctr, Seattle, WA USA
[6] Yale Univ, New Haven, CT USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 1999年 / 44卷 / 04期
关键词
prostate neoplasm; brachytherapy; ultrasound; I-125; Pd-103;
D O I
10.1016/S0360-3016(99)00069-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose/Objective: To develop and disseminate the American Brachytherapy Society (ABS) recommendations for the clinical quality assurance and guidelines of permanent transperineal prostate brachytherapy with I-125 Or Pd-103. Methods and Materials: The ABS formed a committee of experts in prostate brachytherapy to develop consensus guidelines through a critical analysis of published data supplemented by their clinical experience. The recommendations of the panels were reviewed and approved by the Board of Directors of the ABS, Results: Patients with high probability of organ-confined disease are appropriately treated with brachytherapy alone. Brachytherapy candidates with a significant risk of extraprostatic extension should be treated with supplemental external beam radiation therapy (EBRT), Patient selection guidelines were developed. Dosimetric planning of the implant should be carried out for all patients before seed insertion. A modified peripheral loading is preferred. The AAPM TG-43 recommendations requiring a change in prescription dose for I-125 sources should be universally implemented. The recommended prescription doses for monotherapy are 145 Gy for I-125 and 115-120 Gy for Pd-103. The corresponding boost doses (after 40-50 Gy EBRT) are 100-110 Gy and 80-90 Gy, respectively. Clinical evidence to guide selection of radionuclide (Pd-103 Or I-125) is lacking. Post implant dosimetry and evaluation must be performed on all patients. It is suggested that the dose that covers 90% (D-90) and 100% (D-100) of the prostate volume and the percentage of the prostate volume receiving the prescribed dose (V-100) be obtained from a dose-volume histogram (DVH) and reported. Conclusion: Guidelines for appropriate patient selection, dose reporting, and improved quality of permanent prostate brachytherapy are presented. These broad recommendations are intended to be technical and advisory in nature, but the ultimate responsibility for the medical decisions rests with the treating physician. This is a constantly evolving field, and the recommendations are subject to modifications as new data becomes available. (C) 1999 Elsevier Science Inc.
引用
收藏
页码:789 / 799
页数:11
相关论文
共 141 条
  • [51] KANDZARI SJ, 1982, J UROLOGY, V127, P923, DOI 10.1016/S0022-5347(17)54133-6
  • [52] DETAILED PRELIMINARY-ANALYSIS OF I-125 IMPLANTATION FOR LOCALIZED PROSTATE-CANCER USING PERCUTANEOUS APPROACH
    KAYE, KW
    OLSON, DJ
    PAYNE, JT
    [J]. JOURNAL OF UROLOGY, 1995, 153 (03) : 1020 - 1025
  • [53] EXTERNAL BEAM IRRADIATION VERSUS 125-IODINE IMPLANT IN THE DEFINITIVE TREATMENT OF PROSTATE CARCINOMA
    KOPROWSKI, CD
    BERKENSTOCK, KG
    BOROFSKI, AM
    ZIEGLER, JC
    LIGHTFOOT, DA
    BRADY, LW
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1991, 21 (04): : 955 - 960
  • [54] THE SIGNIFICANCE OF POSTIRRADIATION PROSTATE BIOPSY WITH LONG-TERM FOLLOW-UP
    KUBAN, DA
    ELMAHDI, AM
    SCHELLHAMMER, P
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1992, 24 (03): : 409 - 414
  • [55] TRANSPERINEAL PERCUTANEOUS I-125 IMPLANT OF PROSTATE
    KUMAR, PP
    BARTONE, FF
    [J]. UROLOGY, 1981, 17 (03) : 238 - 240
  • [56] THE RELATIVE BIOLOGICAL EFFECTIVENESS OF I-125 AND PD-103
    LING, CC
    LI, WX
    ANDERSON, LL
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 32 (02): : 373 - 378
  • [57] PERMANENT IMPLANTS USING AU-198, PD-103 AND I-125 - RADIOBIOLOGICAL CONSIDERATIONS BASED ON THE LINEAR QUADRATIC MODEL
    LING, CC
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1992, 23 (01): : 81 - 87
  • [58] QUANTIFYING THE EFFECT OF DOSE INHOMOGENEITY IN BRACHYTHERAPY - APPLICATION TO PERMANENT PROSTATIC IMPLANT WITH I-125 SEEDS
    LING, CC
    ROY, J
    SAHOO, N
    WALLNER, K
    ANDERSON, L
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 28 (04): : 971 - 978
  • [59] Seminal vesicle biopsy: Accuracy and implications for staging of prostate cancer
    Linzer, DG
    Stock, RG
    Stone, NN
    Ratnow, R
    Ianuzzi, C
    Unger, P
    [J]. UROLOGY, 1996, 48 (05) : 757 - 761
  • [60] A method for implementing the American Association of Physicists in Medicine Task Group-43 dosimetry recommendations for I-125 transperineal prostate seed implants on commercial treatment planning systems
    Luse, RW
    Blasko, J
    Grimm, P
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 37 (03): : 737 - 741